Hormone replacement therapy and irregular bleeding

Climacteric

Volumn 4, Issue 2, 2001, Pages 95-101

  Hickey, Martha ^a   Higham, J M ^a   Fraser, I S ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; PROGESTERONE; SEX HORMONE;

ANGIOGENESIS; CORRELATION FUNCTION; DRUG EFFECT; EDITORIAL; ENDOMETRIUM; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MENSTRUATION; POSTMENOPAUSE; PRIORITY JOURNAL; VAGINA BLEEDING;

EID: 0034954090     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.4.2.95.101     Document Type: Editorial

References (62)

1. Use of hormone replacement therapy by postmenopausal women in the United States
2. Hormone replacement therapy: Assessment of present use, costs and trends
3. Recent patterns of hormone replacement therapy use in a large managed care organization
4. Regular bleeding on hormone replacement therapy: A myth?
5. What women want from hormone replacement therapy: Results of an international survey
6. Women's beliefs and decisions about hormone replacement therapy
7. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: A cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study
8. Hormone replacement therapy: Cardiovascular benefits for aging women
9. Oestrogen replacement therapy and coronary heart disease
10. Continuous low-dose oestrogen and progestogen hormone replacement therapy: A randomised trial
11. Menstruation
12. Lysosomal concept of menstrual bleeding in humans
13. Hemostasis in menstrual endometrium: A review
14. Expression and localisation of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle
15. Matrix metalloproteinases in normal menstruation
16. Endometrial bleeding in HRT users: Preliminary findings regarding the role of MMP-9 and TIMP-1
17. The immunocytochemical distribution of leukocyte subpopulations in human endometrium
18. Immunohistochemical characterization of stromal leukocytes in nonpregnant human endometrium
19. The effect of high dose medium and long-term progestogen exposure on endometrial vessels
20. Sex steroid receptors in lymphoid cells of the human endometrium
21. The effect of the antiprogestins RU486 and ZK98734 on the synthesis and metabolism of PGF2a and PGE2 in separated cells from early human decidua
22. Endometrial prostaglandins in women with abnormal menstrual bleeding
23. Endothelin-like reactivity in human endometrium
24. Immunolocalisation, binding and biological activity of endothelin in rabbit uterus: Effect of ovarian steroids
25. Cardiovascular, renal and endocrine responses to intravenous endothelin in conscious dogs
26. Studies on the cytodynamics of human endometrial regeneration. I. Scanning electron microscopy
27. Studies on the cytodynamics of human endometrial regeneration. II. Transmission electron microscopy and histochemistry
28. The physiology of menstruation
29. A simple method for determining the optimum dose of progestin in postmenopausal women receiving estrogens
30. Endometrial responses to transdermal estradiol in postmenopausal women
31. Endometrial responses to hormone replacement therapy: Histological features compared with those of late luteal phase endometrium
32. Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding
33. Is the timing of withdrawal bleeding a guide to endometrial safety during cyclic oestrogen-progestagen replacement therapy?
34. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy
35. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: A comparison with postmenopausal bleeding
36. Disturbances of bleeding with hormone replacement therapy
37. A review of the role of progestogens in hormone replacement therapy; influence on bleeding patterns
38. A functional model for progestogen-induced breakthrough bleeding
39. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use
40. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception
41. The endometrial vascular appearance in Norplant users: Preliminary results from an hysteroscopic study
42. Computer-generated, three-dimensional reconstruction of histological parallel serial sections displaying microvascular and glandular structures in human endometrium
43. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel
44. Changes in endometrial vascular density in Norplant users
45. Ovarian steroid and cytokine modulation of human endometrial angiogenesis
46. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium
47. Endothelial cell dysfunction following prolonged activation of progesterone receptor
48. From endometrial receptivity to infertility
49. Perivascular smooth muscle α-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding
50. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium
51. Changes in endothelial cell basement membrane in Norplant users
52. Immunohistochemical study of endometrial microvascular basement membrane components in women using Norplant
53. Granulated lymphocytes in human endometrium: Histochemical and immunohistochemical studies
54. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant)
55. Regulation of matrix metalloproteinases in human endometrium
56. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel
57. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9
58. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrelimplant users
59. Mechanisms of menstrual bleeding: Dysfunctional uterine bleeding and break-through bleeding
60. Benefits of vitamin E supplementation to Norplant users - In vitro and in vivo studies
61. Oxidative stress, vitamin E and progestin breakthrough bleeding